Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.

Niels Jongs,Glenn M Chertow,Tom Greene,John J V McMurray,Anna Maria Langkilde,Ricardo Correa-Rotter,Naoki Kashihara,Peter Rossing,C David Sjöström,Bergur V Stefánsson,Robert D Toto,David C Wheeler,Hiddo J L Heerspink

Journal of the American Society of Nephrology : JASN（2022）

引用 8|浏览13

暂无评分

摘要

Among patients with CKD and albuminuria treated with dapagliflozin, an acute reduction in eGFR (from baseline to 2 weeks) is not associated with higher rates of CKD progression. A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD) NCT03036150.

查看译文

关键词

chronic kidney disease,dapagliflozin,renal function,sodium-glucose transporter 2 inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要